Global pharmaceutical company Lupin Limited announced that China's National Medical Products Administration has approved the shortened marketing authorization application for oseltamivir phosphate submitted by Lupin in partnership with Yabao Pharmaceuticals, a leader in China's pediatric drug market. This is the first time that Lupin is launching a product on the Chinese market. This is an important milestone in the company's global expansion.

Oseltamivir phosphate oral suspension, 6 mg/ml, is being launched and marketed to expand access, particularly for paediatric use. This expands Lupin's global footprint and reinforces its commitment to providing high-quality, affordable medicines to patients and children who need them.

Oseltamivir phosphate oral suspension, 6 mg (base)/ml, is indicated:

• for the treatment of influenza A and B in patients aged 2 weeks and older
• for the prophylaxis of influenza A and B in persons aged 1 year and older

Fabrice Egros, Head of Corporate Development at Lupin, said: "We are very pleased to have received approval for oseltamivir oral suspension in China. This is a strategic step for our entry into one of the world's largest pharmaceutical markets. It reflects our shared commitment to expanding access to high-quality, affordable therapies, especially in pediatric care. We look forward to building a stronger presence in this market through our partnership."

Wei Ren, President of Yabao, said: "We are pleased to announce the official approval of oseltamivir oral suspension in China. It marks an important milestone in our partnership with Lupin. It underlines Yabao's commitment to high-quality paediatric medicines and demonstrates our strong collaboration. We will continue to expand our R&D portfolio for medicines for chronic diseases in children and adults to jointly advance our business."